ロード中...
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States
BACKGROUND: The recently approved drugs, sofosbuvir and ledipasvir, for chronic hepatitis C virus (HCV) treatment are more efficacious and safer but are substantially more expensive than the old standard-of-care (oSOC). It remains unclear whether and in which patients their improved efficacy justifi...
保存先:
| 出版年: | Ann Intern Med |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4435698/ https://ncbi.nlm.nih.gov/pubmed/25775312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M14-1336 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|